Established in 2023, Synta R&D integrates the acquisition of Archimedis Healthcare Limited, a leading Pharmaceutical Research and development facility based in Chennai, India, into the Synta group.  

Synta R&D has MHRA approved manufacturing capability for solid dosage form as well extensive laboratory expertise for the continued development of our portfolio.

The R&D expertise will allow the continued improvement and development of our existing portfolio and the development of new pharmaceutical dossiers to add to our extensive range.